Find out more about how this website uses cookies to enhance your browsing experience.
Accept Cookies
Pfizer, a multinational pharmaceutical and biotechnology business based in the United States, stated that its experimental COVID-19 antiviral can reduce the risk of hospitalization and death in vulnerable adults by 89 percent. On Friday, the business released the preliminary results of the clinical trials.
The treatment, which will be sold under the brand name Paxlovid, was proven to be highly effective in preventing serious illness in vulnerable adults who were given it throughout the research. It's a three-pill combination treatment that's taken twice a day.
Also read What Is COVID-19 Variant R.1? Here's what we've learned so far
The antiviral drug is the second of its sort to be approved for use against Covid.This new antiviral medicine provides better protection than one developed by Merck, another American pharmaceutical company, which is pending approval in the United States but was approved yesterday in the United Kingdom.
The pharmaceutical firm halted the study shortly after the efficacy of the antiviral medicine was proven in the clinical trial.The trial's monitoring board was so convinced, they claimed, that the trial was suspended in its early stages.
The business has not yet released the entire results of the experiment, but they intend to submit the data to the US Food and Drug Administration as soon as possible in order to obtain approval for the pill's use.
After being diagnosed with mild to moderate COVID-19 and having at least one factor that can contribute to severe infection, such as obesity or old age, Pfizer looked at 1,219 people who were at risk of hospitalisation or death.
According to the study, just 0.8 percent of those who were given Pfizer's antiviral drug within three days of the onset of COVID symptoms were hospitalised, and none died within 28 days of treatment.
Also read According to the CDC, side effects from COVID boosters are comparable to those from the second dose
They compared the results to a 7% hospitalization rate for placebo patients, which resulted in seven deaths.
According to the company's statement, based on the study's initial trial, antivirals should be provided as soon as feasible to limit the risk of problems. To be most successful, the medicine must stop the virus from inflicting serious damage before an infection takes hold, which takes three days.
"We saw that we had excellent efficacy, even if it was five days after a patient was treated... folks might wait a few of days before having a test or something, and this indicates that we have time to treat them and actually deliver a public health benefit." Until now, the business has remained tight-lipped about the antiviral drug's negative effects. They merely stated that negative consequences occur 20% of the time.
"These findings suggest that, if approved by regulatory authorities, our oral antiviral candidate could save patients' lives, lessen the severity of COVID-19 infections, and prevent up to nine out of ten hospitalizations," said Pfizer CEO Albert Bourla.
By the end of 2021, Pfizer intends to have produced over 180,000 packs, with at least 50 million by the end of 2022.
© 2024. All rights reserved.
Pfizer, a multinational pharmaceutical and biotechnology business based in the United States, stated that its experimental COVID-19 antiviral can reduce the risk of hospitalization and death in vulnerable adults by 89 percent. On Friday, the business released the preliminary results of the clinical trials.
The treatment, which will be sold under the brand name Paxlovid, was proven to be highly effective in preventing serious illness in vulnerable adults who were given it throughout the research. It's a three-pill combination treatment that's taken twice a day.
Also read What Is COVID-19 Variant R.1? Here's what we've learned so far
The antiviral drug is the second of its sort to be approved for use against Covid.This new antiviral medicine provides better protection than one developed by Merck, another American pharmaceutical company, which is pending approval in the United States but was approved yesterday in the United Kingdom.
The pharmaceutical firm halted the study shortly after the efficacy of the antiviral medicine was proven in the clinical trial.The trial's monitoring board was so convinced, they claimed, that the trial was suspended in its early stages.
The business has not yet released the entire results of the experiment, but they intend to submit the data to the US Food and Drug Administration as soon as possible in order to obtain approval for the pill's use.
After being diagnosed with mild to moderate COVID-19 and having at least one factor that can contribute to severe infection, such as obesity or old age, Pfizer looked at 1,219 people who were at risk of hospitalisation or death.
According to the study, just 0.8 percent of those who were given Pfizer's antiviral drug within three days of the onset of COVID symptoms were hospitalised, and none died within 28 days of treatment.
Also read According to the CDC, side effects from COVID boosters are comparable to those from the second dose
They compared the results to a 7% hospitalization rate for placebo patients, which resulted in seven deaths.
According to the company's statement, based on the study's initial trial, antivirals should be provided as soon as feasible to limit the risk of problems. To be most successful, the medicine must stop the virus from inflicting serious damage before an infection takes hold, which takes three days.
"We saw that we had excellent efficacy, even if it was five days after a patient was treated... folks might wait a few of days before having a test or something, and this indicates that we have time to treat them and actually deliver a public health benefit." Until now, the business has remained tight-lipped about the antiviral drug's negative effects. They merely stated that negative consequences occur 20% of the time.
"These findings suggest that, if approved by regulatory authorities, our oral antiviral candidate could save patients' lives, lessen the severity of COVID-19 infections, and prevent up to nine out of ten hospitalizations," said Pfizer CEO Albert Bourla.
By the end of 2021, Pfizer intends to have produced over 180,000 packs, with at least 50 million by the end of 2022.
Write your first comment.
© 2024. All rights reserved.
Our aim is to offer better technology to healthcare providers who in turn can provide better care for the health seekers.
Just go to the S10.Clinic website and click on the "Book appointment" button on the homepage of the website/app, select a specialty and find the doctor of your choice. Once you select a doctor, you can click on the "Consult Online" button to select your preferred date and time.
Once you select the date and time all you have to do is sign up / login to the platform and make the payment online using your credit / debit card on the Razor pay or CC Avenue gateway. Then, you will receive the consultation link via sms / email.
Our online consultation platform is optimized for the following browsers: Google Chrome and Safari. Please ensure you are free 10 minutes prior to your appointment.
All you have to do is find a well light and quiet place with good internet connectivity, preferably a place with Wi-Fi access. Switch on your microphone (for laptop / mobile and allow browser to access it).
Please note: If you are not able to open the link please delete your browser history and cache files of your browser and try again.
This may happen due to poor internet connectivity. In such cases, please check your internet connection and if the issue persists, please reach out to us at onlineconsulting@s10.clinic with the screenshot of the error and we will get this checked from our end. You can also call us at 044-40510510.
Please note: Please ensure you have given access to your audio and video to your browser in the settings panel.
You will receive an email after the online consultation with the following - Provisional diagnosis, visit notes, prescription and follow up.
Yes. The prescription generated during the online consultation is as good as a physical prescription and will be valid for 6 months from the date of issue (as per government regulations).
You will be able to speak and interact with the doctor only for the time he has specified.
Yes. The e-prescription will be valid for offline pharmacies as well.
Safety of your data is our top priority. We have multi-level security checks, multiple data backups, and stringent policies in place to ensure your data remains safe and secure. Additionally, we are a HIPAA compliant company and we take data privacy and security very seriously. All data on S10.Clinic is secured with 256-bit encryption.
All the patients who use the S10.Clinic platform will be called and verified by our support squad before their consultation with the doctors.
You don't have to worry about it. In that case an automatic refund is initiated from our end, and it will reflect in your bank account within 6-7 business days.
Or you can reach out to us at 044-40510510 or onlineconsulting@s10.clinic and we will be happy to help you.
Don't worry if you've missed the online call with the, you can easily reschedule the call with your preferred doctor 10 minutes prior to any consultation. All you have to do is click on the "Reschedule" option in the appointment email.
Or you can reach out to us at 044-40510510 and we can book the same for you.
Please note: If you do not show up or miss an appointment after your appointment time, you won't be able to reschedule it.
You can reschedule any appointment you make 10 minutes before the consultation free of cost. If you want to reschedule any appointment after the consultation time has started you will have to book a new appointment with your preferred doctor. No refund will be offered in such cases.
After the online consultation you will receive a feedback form where you can rate your experience and tell us what went well, what we need to work on. We take your feedback very seriously and this helps us to improve our app and our services.
We're always there for you! You can reach out to our Support Squad at 044-40510510 or send us an email at onlineconsulting@s10.clinic. You can also dm us on Facebook we will be happy to assist you.
Comments
Write your first comment.